Business Description
Founded in Paris in 1999, Cellectis is a clinical-stage company working to treat cancer and other serious diseases by modifying the genetic makeup of immune cells. Its main focus is on developing off-the-shelf T-cell therapies that can be given to any patient without the need for personalized manufacturing. The company currently has several treatments in clinical testing, targeting blood cancers such as certain types of leukemia and lymphoma, as well as solid tumors including kidney cancer and melanoma.
